TY - JOUR AU - Lee, Lennard Y. W. AU - Mohammad, Summaya AU - Starkey, Thomas AU - Lee, Siow-Ming PY - 2018 TI - STAT3 cyclic oligonucleotide decoy—a new therapeutic avenue for NSCLC? JF - Translational Lung Cancer Research; Vol 7, Supplement 4 (December 30, 2018): Translational Lung Cancer Research Y2 - 2018 KW - N2 - Lung cancer is still the main cause of cancer-related death and accounts for nearly 1.8 million deaths worldwide every year (1,2). About 85–90% of patients with lung cancer have non-small cell lung cancer (NSCLC) with most presenting with advanced metastatic disease. Despite the introduction of immune check-point inhibitors (IO) and newer generation of more effective EGFR TKIs and ALK inhibitors recently, there is still an unmet clinical need for improved treatment options for both wild-type and oncogenic-addicted NSCLC as most of these treated patients still develop disease resistance. Novel treatment strategies including identifying new treatment targets are still needed to improve outcome. UR - https://tlcr.amegroups.org/article/view/24457